REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Fibiomed Sp. z o.o. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Secondary Activities: All Other Food Manufacturing | Pharmaceutical and Medicine Manufacturing | Computer and Electronic Product Manufacturing | Rental and Leasing Services | Scientific Research and Development Services | Office Administrative Services
Full name: Fibiomed Sp. z o.o. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

FiBioMed is a company that specializes in developing and utilizing innovative technology for rapid virus diagnosis, including SARS-CoV-2. The company focuses on creating new diagnostic standards to combat COVID-19 and diagnose other pathogens or diagnostic markers. Their work includes developing a technology for cultivating specific antibodies and a device for fast virus diagnostics, as well as a partly automated device for high-throughput analysis of samples for SARS-CoV-2 that can be easily adapted for other pathogens or diagnostic markers.

Headquarters
Ul. Gleboka 39
Lublin; Lubelskie; Postal Code: 20-612

Contact Details: Purchase the Fibiomed Sp. z o.o. report to view the information.

Basic Information
Total Employees:
Purchase the Fibiomed Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Fibiomed Sp. z o.o. report to view the information.
Financial Auditors:
Purchase the Fibiomed Sp. z o.o. report to view the information.
Incorporation Date:
July 14, 2020
Key Executives
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
82.71%
Company Performance
Financial values in the chart are available after Fibiomed Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
-0.55%▼
Total operating revenue
-20.92%▼
Operating Profit/Loss (EBIT)
-59.16%▼
EBITDA
-58.4%▼
Net Profit/Loss for the Period
-62.33%▼
Total Assets
35.4%▲
Total Equity
N/A
Operating Profit Margin (ROS)
-17221.2%▼
Net Profit Margin
-18582.71%▼
Return on Equity (ROE)
N/A
Quick Ratio
-2.77%▼
Cash Ratio
-0.93%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo